TRZ — Peptide Dosing Protocols reference

patient_educationexpert_opinion · status: needs_provider_review

Details

Author: —

Citation: —

Summary (generated — provider review required)

Tirzepatide Dosing Chart 2026: 2.5-15 mg Titration & Units Shop Protocols Stacks A–Z Index Email Updates Home Protocols Tirzepatide Dosing Chart: 2.5-15 mg Weekly Titration, Reconstitution & Side Effects Protocol / Research Dosing Guide Tirzepatide Dosing Chart: 2.5-15 mg Weekly Titration, Reconstitution & Side Effects Weekly tirzepatide titration from 2.5 mg to 15 mg, mg-to-units conversions across 5/10/15/40/60 mg vials, side effects from SURPASS and SURMOUNT, and how it compares to semaglutide. By Garret Grant · Founder & Lead Researcher · Last reviewed June 2026 · Share Supplier Pick Copy code PEPPAL Copy code PEPPAL Verified Supplier Verified Supplier Peptide Partners Tirzepatide Supply View Supplier Table of Contents View Supplies Quick Start Dosing Protocol & Schedule Supplies Needed Reconstitution Guide Dosage Chart Mechanism Who Should Avoid It Side Effects & Safety Timeline & Monitoring Clinical Evidence Storage & Handling Troubleshooting Regulatory Status Tirzepatide Comparisons Related Protocols Blood Tests FAQ References Tirzepatide Quick Start Disclaimer This page is an educational research and dosing reference. It is not medical advice and does not replace guidance from a licensed clinician.

The original source document remains the source of truth. Generated summaries are not authoritative.

Linked assets (0) · phenotypes (0)

—

Findings (262) · awaiting review (215)

dosing · pending

Each step is a 2.5 mg increment.

safety · pending

Side effect Diarrhea Approx.

safety · pending

Side effect Vomiting Approx.

safety · pending

Side effect Indigestion Approx.

safety · pending

Side effect Injection-site reactions Approx.

safety · pending

Side effect Resting heart rate increas

outcome · pending

Larger increases are uncommon.

safety · pending

Side effect Approx.

dosing · pending

This is what supports once-weekly dosing.

regulatory · pending

Mounjaro / Zepbound Pen Research Vial (mg → units) FDA-approved pen schedule for tirzepatide as Mounjaro (T2D) or Zepbound (obesity / OSA).

dosing · pending

Tirzepatide Titration (Mounjaro and Zepbound) Phase Phase 1 — Init

dosing · pending

iation Weeks Weeks 1–4 Dose 2.5 mg once weekly Notes Tolerability dose.

dosing · pending

Not a therapeutic dose for weight loss or HbA1c.

dosing · pending

By Garret Grant · Founder & Lead Researcher · Last reviewed June 2026 · Share Supplier Pick Copy code PEPPAL Copy code PEPPAL Verified Supplier Verified Supplier Peptide Partners Tirzepatide Supply View Supplier Table of Contents View Supplies Quick Start Dosing Protocol & Schedule Supplies Needed Reconstitution Guide Dosage Chart Mechanism Who Should Avoid It Side Effects & Safety Timeline & Monitoring Clinical Evidence Storage & Handling Troubleshooting Regulatory Status Tirzepatide Comparisons Related Protocols Blood Tests FAQ References Tirzepatide Quick Start Disclaimer This page is an educational research and dosing reference.

safety · pending

Tirzepatide carries a boxed warning for thyroid C-cell tumors.

mechanism · pending

Retatrutide goes one step further by adding glucagon receptor activity, but it remains investigational.

regulatory · pending

Mounjaro is approved for type 2 diabetes.

regulatory · pending

Zepbound is approved for chronic weight management and for obstructive sleep apnea in adults with obesity.

dosing · pending

Both are the same drug, the same molecule, and use the same titration ladder.

dosing · pending

Route Subcutaneous (under-the-skin) injection, once per week, on the same day each week.

dosing · pending

Dose ladder 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg weekly, with at least 4 weeks between steps.

dosing · pending

Measure Most research vials reconstitute cleanly to 20 mg/mL, where 1 mg = 5 units on a U-100 insulin syringe.

regulatory · pending

Research status FDA-approved drug as Mounjaro/Zepbound.

regulatory · pending

Lyophilized research-use vials are a separate, non-FDA grey-market supply.

regulatory · pending

Mounjaro vs Zepbound at a glance Same drug, two indications Active drug Mounjaro Tirzepatide Zepbound Tirzepatide FDA indication Mounjaro Type 2 diabetes Zepbound Chronic weight management; OSA + obesity First approv

dosing · pending

ed Mounjaro May 2022 Zepbound November 2023 Form sold by Lilly Mounjaro Single-use pen Zepbound Single-use pen and vial Titration ladder Mounjaro 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg weekly Zepbound 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg weekly Mounjaro Zepbound Active drug Tirzepatide Tirzepatide FDA indication Type 2 diabetes Chronic weight management; OSA + obesity First approved May 2022 November 2023 Form sold by Lilly Single-use pen Single-use pen and vial Titration ladder 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg weekly 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg weekly The molecule, the dose ladder, and the side-effect profile are identical.

dosing · pending

Tirzepatide Dosing Protocol & Schedule Tirzepatide is dosed once weekly.

dosing · pending

The dose starts low to let the gut adjust, then steps up every 4 weeks.

dosing · pending

The minimum-effective dose for weight loss or glycemic control is 5 mg .

dosing · pending

The maximum studied and approved dose is 15 mg .

dosing · pending

The 2.5 mg, 7.5 mg, and 12.5 mg doses are transitional steps, not long-term targets.

dosing · pending

Tirzepatide Dosing Schedule Choose the format you are researching.

dosing · pending

Phase Phase 2 — Early maintenance Weeks Weeks 5–8 Dose 5 mg once weekly Notes First true maintenance dose.

outcome · pending

Most users feel reduced appetite here.

dosing · pending

Phase Phase 3 — Mid escalation Weeks Weeks 9–12 Dose 7.5 mg once weekly Notes Transitional.

dosing · pending

Phase Phase 4 — Mid maintenance Weeks Weeks 13–16 Dose 10 mg once weekly Notes Second maintenance dose.

dosing · pending

Phase Phase 5 — High escalation Weeks Weeks 17–20 Dose 12.5 mg once weekly Notes Transitional.

dosing · pending

Phase Phase 6 — Maximum dose Weeks Weeks 21+ Dose 15 mg once weekly Notes Maximum FDA-approved dose.

dosing · pending

Phase Weeks Dose Notes Phase 1 — Initiation Weeks 1–4 2.5 mg once weekly Tolerability dose.

Processing

Processed into 34 searchable sections.